Novo Nordisk Stock Falls 6% on Hims & Hers Health Dispute

Novo Nordisk stock is falling 6% in pre-market trade after announcing that it will no longer work with Hims & Hers Health due to concerns over compounded drugs with illicit active pharmaceutical ingredients. The company said it is taking measures to keep US patients safe from knock-off drugs made in China. Novo Nordisk will provide direct access to Wegovy to telehealth companies that share its commitment to patient safety.

Novo Nordisk's (NVO) stock fell by 6% in pre-market trading following the company's announcement that it will no longer collaborate with Hims & Hers Health, Inc. due to concerns over illegal mass compounding and deceptive marketing practices [1].

The termination of the partnership comes after Novo Nordisk discovered that Hims & Hers was selling knockoff versions of Wegovy, an injectable prescription medicine used for weight management and reducing the risk of major cardiovascular events. These knockoffs were sourced from unauthorized Chinese manufacturers, raising significant safety concerns [1].

The FDA had previously resolved the Wegovy shortage in April 2025, confirming Novo Nordisk's ability to meet current and projected demand. This resolution eliminated the need for alternative compounded versions of Wegovy, which could potentially compromise patient safety [1].

In response to these developments, Novo Nordisk will continue to supply authentic Wegovy exclusively through NovoCare Pharmacy to telehealth organizations that uphold safe medical practices. This strategic move aims to maintain product integrity and prevent illegal compounding activities that pose risks to patient health [1].

Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc., stated, "Novo Nordisk is firm on our position and protecting patients living with obesity. When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy®" [2].

The company is taking proactive measures to ensure US patients are not exposed to knock-off drugs made with unsafe and illicit foreign ingredients. According to a report from the Brookings Institute, the FDA has never authorized or approved the manufacturing processes used by any of these foreign suppliers to make semaglutide [2].

Novo Nordisk's commitment to patient safety remains a top priority, and the company will continue to work with telehealth companies to provide direct access to Wegovy® [2].

References:
[1] https://www.gurufocus.com/news/2938908/novo-nordisk-terminates-collaboration-with-hims-hers-health-inc-due-to-concerns-about-their-illegal-mass-compounding-and-deceptive-marketing-nvo-stock-news
[2] https://www.prnewswire.com/news-releases/novo-nordisk-terminates-collaboration-with-hims--hers-health-inc-due-to-concerns-about-their-illegal-mass-compounding-and-deceptive-marketing-302488189.html